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Tuberculosis and vitamin D: what's the rest of the story?
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Both protein–energy undernutrition and specific micronutrient deficiencies debilitate the 
cell-mediated immune system important in protection against tuberculosis.1 However, once 
tuberculosis de velops, the disease itself induces a catabolic state resulting in negative 
nitrogen balance and micronutrient deficiencies. Generations of clinicians treating patients 
with tuberculosis believed that nutritional support was crucial to proper patient care. Why, 
then, has it been so difficult to prove through randomised controlled clinical trials that 
nutritional interventions improve tuberculosis treatment outcomes? Findings from 
systematic reviews2–6 have not shown any clear, consistent benefit in terms of tuberculosis-
specific outcomes, although they do show improvements in nutritional status.
In the past 30 years, researchers have discovered many roles and mechanisms of vitamin D 
action in both the innate and adaptive immune systems.7 Vitamin D promotes macrophage-
mediated killing of Mycobacterium tuberculosis,8 an observation that has led to several 
phase 2 trials2–6 of vitamin D sup plementation, nearly all of which have shown no 
substantial benefit in terms of tuberculosis treatment outcomes. In The Lancet Infectious 
Diseases, Peter Daley and colleagues9 report findings from another such trial, and again the 
findings are negative. The randomised, double-blind, placebo-controlled trial was well 
designed to address an important issue with use of an inexpensive, simple intervention. 
Study treatment was given under direct observation; randomisation involved well concealed 
treatment allocation; masking of the intervention between the groups was reportedly good; 
at baseline the study groups were reasonably matched, although pulmonary cavitation was 
unknown; assessment of endpoints was masked; dedicated study staff collected all patient 
data; smears and cultures were processed in one laboratory by one experienced technologist 
who was masked to treatment allocation; and withdrawals, exclusions, and dropouts were 
noted. Thus, the methods seem to be robust, despite the absence of a traditional CONSORT 
diagram or use of multivariable regression methods in the analysis. Furthermore, the trial 
was reasonably powered for its primary outcome of time to sputum culture conversion. 
Median time to sputum culture conversion was similar between participants in the vitamin D 
and placebo groups (43·0 days [95% CI 33·3–52·8] and 42·0 days [33·9–50·1], respectively), 
as were the proportions of patients with positive sputum cultures at 2 months. Does this 
mean that vitamin D supplementation is of no value in the management of pulmonary 
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tuberculosis? The answer is not yet clear, but different questions should now be asked. 
Although vitamin D stimulates macrophage-mediated killing of M tuberculosis through the 
innate immune system, it also regulates this response by inducing mechanisms to inactivate 
some aspects of the immune responses and modulate others. Vitamin D itself induces 
mechanisms for inactivation of vitamin D and vitamin D-mediated innate immune responses 
and inflammation.10 In terms of the adaptive immune response, vitamin D suppresses T-
helper type 1 cellular responses crucial in host defense against tuberculosis, promoting a T-
helper type 2 predominance associated with immunological tolerance, humoral immunity, 
and defense against viral infections.11 An extensive body of scientific literature has 
developed elucidating the effects of vitamin D on these and other cellular components of the 
immune system, many of which have suppressor functions.7,12
Some research has suggested that the antimyco-bacterial activity of vitamin D might operate 
at the level of the initial implantation and ingestion of bacilli by alveolar macrophages and 
tissue dendritic cells.13,14 In other words, vitamin D might also be important for prevention 
of symptomatic disease. Rather than pharmacological doses given at discrete moments after 
a patient develops active disease, a constant level of vitamin D sufficiency might be 
important in the bolstering of resistance to tuberculosis so that the initial response to an 
inhaled bacillus is optimum at the moment it happens. This initial response is dependent not 
only on vitamin D, but also on various micronutrients and protein–energy nutrition, so 
optimisation of this initial response might require consideration of nutritional status more 
broadly.
Trials assessing sputum conversion could be misdirected if the major action of vitamin D, in 
the context of active tuberculosis disease, is to mitigate the inflammatory and immune 
response.4,5 This function would be better shown through restriction of tissue damage or 
prevention of relapse, rather than with acceleration of sputum conversion; however, such 
trials are longer and more difficult and costly to perform. A therapeutic effect might be 
assessed by addition of a vitamin D intervention to a large phase 3 trial with a factorial 
design. The results of recent clinical trials and advances in immunology suggest that 
investigation of the role of vitamin D in tuberculosis prevention might be fruitful.
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